Literature DB >> 31615865

New Approaches on Cancer Immunotherapy.

Jong-Ho Cha1,2, Li-Chuan Chan1,3, Min Sup Song1, Mien-Chie Hung1,3,4,5.   

Abstract

Metastasis, which occurs when cancer cells disseminate from the primary tumor site to other parts of the body, is the primary cause of mortality in patients, and the recurrence of multiple metastatic tumors is an obstacle to eliminating cancer. Recent clinical studies demonstrated that patients who respond to immunotherapy have longer survival rates with lower metastatic relapse, suggesting that immunotherapy may be one of the solutions to overcome cancer metastasis. Indeed, various host immune cells not only shape the tumor microenvironment but also participate in multiple stages of metastasis. Therefore, to improve clinical outcome, it is critical to understand the immunological events associated with tumor development and progression. In this article, we summarize those events that are involved in tumor progression and discuss immunotherapies that can potentially target cancer metastasis.
Copyright © 2020 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 31615865      PMCID: PMC7156317          DOI: 10.1101/cshperspect.a036863

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   5.159


  124 in total

1.  The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.

Authors:  Vyara Matson; Jessica Fessler; Riyue Bao; Tara Chongsuwat; Yuanyuan Zha; Maria-Luisa Alegre; Jason J Luke; Thomas F Gajewski
Journal:  Science       Date:  2018-01-05       Impact factor: 47.728

2.  Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth.

Authors:  Yi Yang; Chia-Wei Li; Li-Chuan Chan; Yongkun Wei; Jung-Mao Hsu; Weiya Xia; Jong-Ho Cha; Junwei Hou; Jennifer L Hsu; Linlin Sun; Mien-Chie Hung
Journal:  Cell Res       Date:  2018-06-29       Impact factor: 25.617

Review 3.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

Review 4.  IL-2: the first effective immunotherapy for human cancer.

Authors:  Steven A Rosenberg
Journal:  J Immunol       Date:  2014-06-15       Impact factor: 5.422

5.  Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice.

Authors:  Jean Albrengues; Mario A Shields; David Ng; Chun Gwon Park; Alexandra Ambrico; Morgan E Poindexter; Priya Upadhyay; Dale L Uyeminami; Arnaud Pommier; Victoria Küttner; Emilis Bružas; Laura Maiorino; Carmelita Bautista; Ellese M Carmona; Phyllis A Gimotty; Douglas T Fearon; Kenneth Chang; Scott K Lyons; Kent E Pinkerton; Lloyd C Trotman; Michael S Goldberg; Johannes T-H Yeh; Mikala Egeblad
Journal:  Science       Date:  2018-09-28       Impact factor: 47.728

Review 6.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

Authors:  M B Atkins; M T Lotze; J P Dutcher; R I Fisher; G Weiss; K Margolin; J Abrams; M Sznol; D Parkinson; M Hawkins; C Paradise; L Kunkel; S A Rosenberg
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

Review 7.  Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?

Authors:  Inge Marie Svane; Els M Verdegaal
Journal:  Cancer Immunol Immunother       Date:  2014-08-07       Impact factor: 6.968

8.  Mechanisms driving local breast cancer recurrence in a model of breast-conserving surgery.

Authors:  Myles J Smith; Aedín C Culhane; Shane Killeen; Maura A Kelly; Jiang H Wang; Thomas G Cotter; Henry P Redmond
Journal:  Ann Surg Oncol       Date:  2008-07-12       Impact factor: 5.344

9.  Molecular mechanisms of treg-mediated T cell suppression.

Authors:  Angelika Schmidt; Nina Oberle; Peter H Krammer
Journal:  Front Immunol       Date:  2012-03-21       Impact factor: 7.561

10.  Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.

Authors:  Mauro Poggio; Tianyi Hu; Chien-Chun Pai; Brandon Chu; Cassandra D Belair; Anthony Chang; Elizabeth Montabana; Ursula E Lang; Qi Fu; Lawrence Fong; Robert Blelloch
Journal:  Cell       Date:  2019-04-04       Impact factor: 41.582

View more
  2 in total

1.  COVID-19-associated lncRNAs as predictors of survival in uterine corpus endometrial carcinoma: A prognostic model.

Authors:  Yang Ding; Xia Li; Jiena Li
Journal:  Front Genet       Date:  2022-09-06       Impact factor: 4.772

Review 2.  A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity.

Authors:  KyeongJin Kim; Wen-Hao Yang; Youn-Sang Jung; Jong-Ho Cha
Journal:  BMB Rep       Date:  2020-11       Impact factor: 4.778

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.